Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults (SASOV)
Surgery Versus Intra-lesional Sclerosis With Polidocanol (Aetoxisclerol) in Labial Venous Malformations in Children and Adults: a Randomized Controlled Trial
The goal of this clinical trial is to learn if Surgery works better than Intra-lesional Sclerosis With Polidocanol to treat Labial Venous Malformations in Children and Adults. It will also learn about the safety of both approaches. The main questions it aims to answer are:
- Does Surgery has greater Global efficacy, including (including lesion volume reduction, scar quality, and lip symmetry) than Intra-lesional Sclerosis With Polidocanol?
- What complications do participants have when undergoing Surgery or Intra-lesional Sclerosis With Polidocanol? Researchers will compare surgery to Intra-lesional Sclerosis With Polidocanol.
Participants will be randomized to one of two treatment strategies:
- Experimental group: Surgical excision of the labial venous malformation (VM).
- Control group: Sclerotherapy strategy consisting of one or two sessions of intralesional polidocanol 3% injection.
Patients will be identified and recruited during multidisciplinary vascular anomalies clinics. The study protocol will be explained to eligible patients and their families. After obtaining written informed consent (or consent from both parents together with the child's assent, when applicable), participants will be enrolled in the study.
Following enrollment, participants will be randomly assigned to one of the two parallel treatment groups. A baseline assessment will be performed, and patients will receive a patient diary to record subjective outcomes, including pain, during the pre-intervention period until the date of the procedure.
Study follow-up visits will take place at 1 month (telemedicine visit), 3 months, and 12 months after treatment. Outcome assessments will be performed at each scheduled follow-up visit.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Fáze 3
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Aline JOLY, MD
- Telefonní číslo: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
Studijní záloha kontaktů
- Jméno: Coralie TAILLEBUIS
- Telefonní číslo: +33247473909
- E-mail: c.taillebuis@chu-tours.fr
Studijní místa
-
-
-
Paris, Francie
- Lariboisière
-
Kontakt:
- Annouk BISDORFF, MD
- Telefonní číslo: +331 49 95 84 50
- E-mail: annouk.bisdorff@aphp.fr
-
Kontakt:
- E-mail: a.joly@chu-tours.fr
-
Vrchní vyšetřovatel:
- Annouk BISDORFF, MD
-
Paris, Francie
- Necker
-
Kontakt:
- Olivia BOCCARA, MD
- Telefonní číslo: +331 44 49 46 63
- E-mail: olivia.boccara@aphp.fr
-
Vrchní vyšetřovatel:
- Olivia BOCCARA, MD
-
Tours, Francie
- CHRU de Tours
-
Kontakt:
- Aline JOLY, MD
- Telefonní číslo: +332 47 47 38 21
- E-mail: a.joly@chu-tours.fr
-
Kontakt:
- E-mail: a.joly@chu-tours.fr
-
Vrchní vyšetřovatel:
- Aline JOLY, MD
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- Age ≥ 4 years
- Symptomatic venous malformation of the lower and/or upper lip
- Venous pocket with an area of between 10 and 50 mm²
- No history of surgery or interventional radiology in the area within the two years prior to inclusion
- Suitable for sclerotherapy and surgery
- Patient covered by the National Health Service
- Informed, written consent from the child's legal guardians or from the participant themselves if they are of legal age
Exclusion Criteria:
- Pregnant or breastfeeding women
- Women of childbearing age not using effective contraception throughout the study
- Patients under guardianship or curatorship, or subject to a court-ordered protective measure
- Other vascular abnormalities
- Contraindications to MRI
- Contraindications to Aetoxisclerol®
- Contraindications to general anaesthesia
- Contraindications to surgery
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Singl
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Surgical strategy
Experimental group: Surgical strategy for the excision of the superficial venous malformation (SVM). The surgery involves either partial reconstructive excision or complete excision of the SVM, depending on its size. The aim is to restore symmetry to the affected side of the lip in order to correct functional impairments and aesthetic effects. |
The surgery is performed under local or general anaesthesia (depending on the size of the SVM and the patient's age). Various coagulation devices (monopolar forceps with a Colorado tip, bipolar scissors, etc.) are used to section and dissect the SVM and to control haemostasis. |
|
Aktivní komparátor: Sclerotherapy strategy
Control group: Sclerotherapy strategy comprising one to two sessions of intra-lesional sclerotherapy with 3% polidocanol (Aetoxisclerol). |
The procedure may be carried out under local or general anaesthesia, depending on the patient's age, anticipated tolerance and in accordance with standard practice at the centre. The patient is positioned in the supine position. Following manual and visual localisation of the target lesion, one or more needles of 30/100th to 18G gauge are inserted, and their position within the lesion is confirmed by gentle aspiration, which should yield blood without resistance. The injection of an iodinated contrast medium suitable for intravenous use, to characterise the drainage and under fluoroscopic guidance in the angiography suite, is recommended but not mandatory. Once in place, ≤ 2 mg/kg of polidocanol is injected per session, i.e. ≤ 0.067 mL/kg of 3% solution distributed amongst the needles (1/2 to 2 ampoules), until thrombosis occurs, significant tension is felt in the lesion, or pain develops. Sclerotherapy may be repeated if necessary between 3 and 6 months after the first session. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Global change
Časové okno: From enrollment to Month 12 post intervention
|
Global change will be assessed 12 months after the intervention using a Likert scale ranging from -5 to +5 (0 = no improvement or worsening, higher scores mean better outcome), based on standardized pre- and post-intervention photographs. Assessments will be performed by an independent review panel comprising three physicians (one surgeon, one dermatologist, and one interventional radiologist) and one patient with a labial VM who did not participate in the study. The evaluation will be performed blinded to treatment allocation and will encompass changes in lesion volume, scar quality, and lip symmetry. A standardized photography protocol will be used. This primary endpoint (photograph-based assessment by an independent review panel) was selected to limit bias related to the open-label nature of the study, consistent with a PROBE design (Prospective Randomized Open, Blinded Endpoint). |
From enrollment to Month 12 post intervention
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Aesthetic impact of the venous malformation
Časové okno: Month 0 and Month 12
|
Assessment of aesthetic burden using a 0 to 10 visual analogue scale (VAS) with higher scores mean worse outcome, measured at baseline and 12 months after the intervention. |
Month 0 and Month 12
|
|
Functional impact: overall mouth function
Časové okno: Month 0 and Month 12
|
Functional impact assessed using a 0 to 10 Visual Analogue Scale (VAS) for overall mouth function, with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: lip continence
Časové okno: Month 0 and Month 12
|
Quantification of lip continence using a self-administered drooling questionnaire (Drooling Severity and Frequency Scale [DSFS]), score ranging from 2 to 9 with higher scores mean worse outcome |
Month 0 and Month 12
|
|
Functional impact: speech intelligibility
Časové okno: Month 0 and Month 12
|
Speech intelligibility assessed using a self-administered questionnaire measuring speech-related intelligibility, the Intelligibility in Context Scale (ICS). Score ranging from 7 to 35, with higher scores mean better outcome |
Month 0 and Month 12
|
|
Overall patient satisfaction: Likert scale
Časové okno: From enrollment to Month 12
|
Overall patient satisfaction assessed with a Likert scale ranging from -5 to +5 (0 = no improvement and no worsening), higher scores mean better outcome |
From enrollment to Month 12
|
|
Overall patient satisfaction: Goal Attainment Scale
Časové okno: Month 12
|
Using achievement of personalized goals (maximum of three), predefined by the patient together with the investigator, assessed with the Goal Attainment Scale (GAS; scores ranging from -2 to +2, with higher scores mean better outcome). The Goal Attainment Scale (GAS) is a method for measuring treatment effectiveness by creating patient-specific outcome scales that are predefined before study participation. GAS aims to identify goals that are meaningful to the patient and related to their daily activities and individual priorities (Steinbook RM, 1977; DOI: 10.1001/archpsyc.1977.01770200061005). |
Month 12
|
|
Number of painful days: Total number of painful days
Časové okno: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
Total number of painful days assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post intervention visit (M12)
|
|
Number of painful days: Number of painful days with a VAS pain score > 3/10
Časové okno: The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
Number of painful days with a VAS pain score > 3/10 assessed using either a patient diary or the online ePRO portal. |
The month (30 days) preceding the intervention, the month following the intervention, and the month preceding the 12-month post-intervention visit (M12)
|
|
Venous Malformation volume on MRI
Časové okno: Month 0 and Month 12
|
Venous malformation volume assessed before the intervention (within 6 months prior to treatment) and 12 months after the intervention (performed as part of routine care). Volumetric assessment will be conducted using a semi-automated thresholding method. Image analysis will be centralized and performed by an independent radiologist blinded to treatment allocation. |
Month 0 and Month 12
|
|
Coagulation: D-dimer
Časové okno: Month 12
|
D-dimer |
Month 12
|
|
Coagulation: fibrinogen level
Časové okno: Month 12
|
Fibrinogen level |
Month 12
|
|
Adverse events including complications
Časové okno: From enrollment to Month 12
|
Safety including adverse events and complications, recorded using a patient diary or the online ePRO portal |
From enrollment to Month 12
|
|
Acceptability of the interventions
Časové okno: Month 1, Month 3 , and Month 12
|
Acceptability of the interventions for the patient (or for parents in children aged < 6 years), assessed using a 0 to 10 Visual Analogue Scale (VAS), with higher scores mean worse outcome |
Month 1, Month 3 , and Month 12
|
|
Healthcare costs
Časové okno: From enrollment to Month 12 following the intervention
|
In each arm, patients' healthcare utilization related to the procedure and outpatient care will be measured using hospital databases and a patient diary, then valued in euros from the perspective of the healthcare system. |
From enrollment to Month 12 following the intervention
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- DR240317
- 2025 (Grant/smlouva NIH USA)
- 2025-521374-34-00 (Ctis)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .